The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -31.24 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.45 — no flag raisedOK
- Earnings quality 61/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Bionano Genomics, Inc. reports it. History and quarterly detail are in the app.
- Product$26.7M
- Consumable Revenue$14.0M
- Software Revenue$6.4M
- Instrument Revenue$6.4M
- Product And Service Other$1.8M
Leadership changes
From Bionano Genomics, Inc.'s own filings, the day they're filed.
- Alka Chaubey · Chief Medical Officer · departureeff. 2026-07-05
- Kristiina Vuori · Directors · appointmenteff. 2025-06-10
- R. Erik Holmlin · principal financial officer · appointmenteff. 2024-09-18
Latest filings
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Bionano Genomics, Inc., every answer cited🔒
- The Intelligence Brief — added when Bionano Genomics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.